Cost comparisons of available brands of insulin glargine preparations

Authors

  • Vikram Anant Rajadnya Department of Pharmacology, D. Y. Patil Medical College, Kolhapur, Maharashtra, India http://orcid.org/0000-0002-5388-0289
  • Diya Amol More D. Y. Patil Medical College, Kolhapur, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20212381

Keywords:

Insulin glargine vials 100 units/ml, Cost, Annual cost

Abstract

Background: The objective was to study the annual cost of each of the four important brands of insulin glargine available in India and to study the comparative annual cost of all the four brands.

Methods: Four most commonly prescribed brands of insulin glargine vials were selected for cost comparisons. The daily as well as annual cost of prescription of insulin glargine vials based on once daily use was worked out directly as well as in percentages and presented in the form of table and bar diagrams.

Results: After careful analysis of the data it was found that the costliest brand, brand D is more than two times costlier than the cheapest brand, brand B and thus the brand preparation selection, can lead to huge difference in annual cost burden to the patient.

Conclusions: This significant cost difference between costliest and cheapest brands of insulin glargine vials assumes even further importance since majority of the diabetics need to bear the cost of multiple drugs prescribed to them, on their own. Thus it rather becomes a duty of the prescribing health care provider to prescribe those medicines which are cost effective to his/her patients.

Author Biography

Vikram Anant Rajadnya, Department of Pharmacology, D. Y. Patil Medical College, Kolhapur, Maharashtra, India

MBBS STUDENT

References

Reitzle L, Schmidt C, Scheidt-Nave C, Ziese T. An international comparison of non-communicable disease reporting: the case of diabetes mellitus. J Health Monitor. 2019;4(2):64.

American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(1):8-16.

Drugs.com. Fact sheet: Diabetes Mellitus, 2020. Available at: https://www.drugs.com/health-guide/diabetes-mellitus.html. Accessed on 5 May 2021.

Candido R, Wyne K, Romoli E. A review of basal bolus therapy using insulin glargine and insulin Lispro in the management of diabetes mellitus. Diabetes Ther. 2018;9(3):927-49.

Gu T, Hong T, Zhang P, Tang S, Bi Y, Lu H, et al. Insulin glargine combined with oral antidiabetic drugs for asians with type 2 diabetes mellitus: a pooled analysis to identify predictors of dose and treatment response. Diabetes Ther. 2018;9(2):771-87.

Drugs.com. Fact sheet: Insulin glargine dosages, 2020. Available at: https://www.drugs.com/dosage/insulin-glargine.html. Available on 5 May 2021.

Netmeds.com. Fact sheet: Insulin glargine 100 U/ml, 2020. Available at: https://m.netmeds.com/generics/insulin-glargine-100iu. Accessed on 5 May 2021.

National institute of Nutrition (NIN), Indian Council of medical research (ICMR); A Reports of The Expert Group 2020, Nutrient requirements For Indians; 2020 ; page 1. Availabel at: https://www.nin.res.in/. Accessed on 20 May 2021.

Sharifnia SHA, Mohammadzadeh M, Arzani G, Salamzadeh J, Abolfazli SA, Zali A, et al. Main factors affecting physicians prescribing decisions, the Iranian experience. Iran J Pharm Res. 2018;17(3):1105-15.

Shijit VP, Sekher TV. Who gets health insurance coverage in India? New findings from nationwide surveys. XXVII IUSSP Int Populat Confer Busan. Available at: https://iussp.org/. Accessed on 20 May 2021.

Downloads

Published

2021-06-22

How to Cite

Rajadnya, V. A., & More, D. A. (2021). Cost comparisons of available brands of insulin glargine preparations. International Journal of Basic & Clinical Pharmacology, 10(7), 830–833. https://doi.org/10.18203/2319-2003.ijbcp20212381

Issue

Section

Original Research Articles